Q-omics provides the consensus-scored MTRNR2L4 profile across patient tissues and cancer cell-line models. MTRNR2L4 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, MTRNR2L4 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, MTRNR2L4 RNA expression shows 17,264 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SCLC, THCA, and THYM as cancer lineages where MTRNR2L4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTRNR2L4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTRNR2L4 survival associations across molecular data types. MTRNR2L4 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTRNR2L4 RNA expression–survival associations across cancer types. High MTRNR2L4 expression shows unfavorable associations in STAD, DLBC and BLCA, but favorable associations in SCLC, HNSC and ACC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for MTRNR2L4 RNA expression.
This table summarizes MTRNR2L4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MTRNR2L4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTRNR2L4 shows lower tumor expression in THCA and ESCA and higher tumor expression in LIHC, PRAD, HNSC and CHOL. The THCA box plot shows higher MTRNR2L4 RNA expression in normal versus tumor tissue (log2 FC = −0.173, t-test p < 0.001).
This table shows molecular features associated with MTRNR2L4 in patient tissues and cancer cell lines. In patient samples, MTRNR2L4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MTRNR2L4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS.
